deltatrials
No Longer Available EXPANDED_ACCESS NCT06331832

Expanded Access of Imvotamab (IGM-2323) in Patients With R/R NHL

Treatment Guidelines for Expanded Access of Imvotamab (IGM-2323) in Patients With Relapsed/Refractory Non-Hodgkin Lymphomas From IGM-2323-001

Sponsor: IGM Biosciences, Inc.

Conditions Relapsed/Refractory Non-Hodgkin Lymphomas
Interventions IGM2323
Updated 4 times since 2024 Last updated: Mar 19, 2024
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT06331832, this observational or N/A phase trial focuses on Relapsed/Refractory Non-Hodgkin Lymphomas and remains ongoing. Sponsored by IGM Biosciences, Inc., it has been updated 4 times since 2026, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

~Apr 2024 – ~Jul 2024 · 3 months · monthly snapshotNo Longer Available~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Sep 2025 · 12 months · monthly snapshotNo Longer Available~Sep 2025 – present · 10 months · monthly snapshotNo Longer Available

Change History

4 versions recorded

  1. Sep 2025 — Present [monthly]

    No Longer Available

  2. Sep 2024 — Sep 2025 [monthly]

    No Longer Available

  3. Jul 2024 — Sep 2024 [monthly]

    No Longer Available

  4. Apr 2024 — Jul 2024 [monthly]

    No Longer Available

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • IGM Biosciences, Inc.
Data source: IGM Biosciences, Inc.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations